APA (7th ed.) Citation

Hofheinz, R., Herrle, F., Dechow, T., von Weikersthal, L. F., Welslau, M., Lettmaier, S., . . . Gaiser, T. (2025). Corrigendum to “mFOLFOX6 versus mFOLFOX6 + aflibercept as neoadjuvant treatment in MRI-defined T3-rectal cancer: A randomized phase-II-trial of the German Rectal Cancer Study Group (CAO/ARO/AIO 0214) and the ABCSG (R-06)”$d[ESMO Open 9 (2024) 103703] : corrigendum. ESMO open, 10(2), . https://doi.org/10.1016/j.esmoop.2024.104095

Chicago Style (17th ed.) Citation

Hofheinz, Ralf-Dieter, et al. "Corrigendum to “mFOLFOX6 Versus MFOLFOX6 + Aflibercept as Neoadjuvant Treatment in MRI-defined T3-rectal Cancer: A Randomized Phase-II-trial of the German Rectal Cancer Study Group (CAO/ARO/AIO 0214) and the ABCSG (R-06)”$d[ESMO Open 9 (2024) 103703] : Corrigendum." ESMO Open 10, no. 2 (2025). https://doi.org/10.1016/j.esmoop.2024.104095.

MLA (9th ed.) Citation

Hofheinz, Ralf-Dieter, et al. "Corrigendum to “mFOLFOX6 Versus MFOLFOX6 + Aflibercept as Neoadjuvant Treatment in MRI-defined T3-rectal Cancer: A Randomized Phase-II-trial of the German Rectal Cancer Study Group (CAO/ARO/AIO 0214) and the ABCSG (R-06)”$d[ESMO Open 9 (2024) 103703] : Corrigendum." ESMO Open, vol. 10, no. 2, 2025, https://doi.org/10.1016/j.esmoop.2024.104095.